Multi-partner approach for IDRI's leishmaniasis vaccine in India
This article was originally published in Scrip
Just announced plans to develop and commercialize the Infectious Disease Research Institute's (IDRI) visceral leishmaniasis (VL) vaccine candidate in India are expected to involve a multi-partner approach, with the domestic firms Zydus Cadila and Gennova Biopharmaceuticals working on a potential alliance in the production area.
You may also be interested in...
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.